We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Pegfilgrastim Prophylaxis Is Effective in the Prevention of Febrile Neutropenia and Reduces Mortality in Patients Aged ≥ 75 Years with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Prospective Cohort Study.
- Authors
Seong Hyun Jeong; Seok Jin Kim; Dok Hyun Yoon; Yong Park; Hye Jin Kang; Youngil Koh; Gyeong-Won Lee; Won-Sik Lee; Deok-Hwan Yang; Young Rok Do; Min Kyoung Kim; Kwai Han Yoo; Yoon Seok Choi; Hwan Jung Yun; Jun Ho Yi; Jae-Cheol Jo; Hyeon-Seok Eom; Jae-Yong Kwak; Ho-Jin Shin; Byeong Bae Park
- Abstract
Purpose Febrile neutropenia (FN) can cause suboptimal treatment and treatment-related mortality (TRM) in diffuse large B-cell lymphoma (DLBCL) patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP). Materials and Methods We conducted a prospective cohort study to evaluate the effectiveness of pegfilgrastim prophylaxis in DLBCL patients receiving R-CHOP, and we compared them with the PROCESS cohort (n=485). Results Since January 2015, 986 patients with DLBCL were enrolled. Pegfilgrastim was administered at least once in 930 patients (94.3%), covering 90.3% of all cycles. FN developed in 137 patients (13.9%) in this cohort (23.7% in the PROCESS cohort, p < 0.001), and 4.2% of all cycles (10.2% in the PROCESS cohort, p < 0.001). Dose delay was less common (≥ 3 days: 18.1% vs. 23.7%, p=0.015; ≥ 5 days: 12.0% vs. 18.3%, p=0.023) in this cohort than in the PROCESS cohort. The incidence of TRM (3.2% vs. 5.6%, p=0.047) and infection-related death (1.8% vs. 4.5%, p=0.004) was lower in this cohort than in the PROCESS cohort. The 4-year overall survival (OS) and progression-free survival (PFS) rates of the two cohorts were not different (OS: 73.0% vs. 71.9%, p=0.545; PFS: 69.5% vs. 68.8%, p=0.616). However, in patients aged ≥ 75 years, the 4-year OS and PFS rates were higher in this cohort than in the PROCESS cohort (OS: 49.6% vs. 33.7%, p=0.032; PFS: 44.2% vs. 30.3% p=0.047). Conclusion Pegfilgrastim prophylaxis is effective in the prevention of FN and infection-related death in DLBCL patients receiving R-CHOP, and it also improves OS in patients aged ≥ 75 years.
- Subjects
DIFFUSE large B-cell lymphomas; FILGRASTIM; FEBRILE neutropenia; ANTINEOPLASTIC combined chemotherapy protocols; COHORT analysis
- Publication
Cancer Research & Treatment, 2022, Vol 54, Issue 4, p1268
- ISSN
1598-2998
- Publication type
Article
- DOI
10.4143/crt.2021.1168